User login
PARIS — An investigational anti-inflammatory drug shows promise in reducing the severity of mild to moderate atopic dermatitis, Dr. Karl Beutner said in a poster presentation at the annual meeting of the European Society for Dermatological Research.
A total of 103 patients with mild to moderate atopic dermatitis (body surface area 3%–10%) were randomized to twice-daily treatment with 1% AN0128 (67 patients)—AN0128 has been shown to block inflammatory cytokines in vitro—or the vehicle cream (36 patients) for 4 weeks, wroteDr. Beutner, chief medical officer of Anacor Pharmaceuticals Inc. in Palo Alto, Calif.
Subjects were evaluated with the six-point Investigator's Static Global Assessment at baseline and on days 3, 7, 14, 28, and 35. With the ISGA, patients are rated as clear, almost clear, mild, moderate, severe, or very severe. Treatment success was defined as a rating of clear or almost clear. All other ratings were treatment failures.
At the end of 4 weeks, 51% of the AN0128 group reached a level of clear or almost clear, vs. 37% of controls.
PARIS — An investigational anti-inflammatory drug shows promise in reducing the severity of mild to moderate atopic dermatitis, Dr. Karl Beutner said in a poster presentation at the annual meeting of the European Society for Dermatological Research.
A total of 103 patients with mild to moderate atopic dermatitis (body surface area 3%–10%) were randomized to twice-daily treatment with 1% AN0128 (67 patients)—AN0128 has been shown to block inflammatory cytokines in vitro—or the vehicle cream (36 patients) for 4 weeks, wroteDr. Beutner, chief medical officer of Anacor Pharmaceuticals Inc. in Palo Alto, Calif.
Subjects were evaluated with the six-point Investigator's Static Global Assessment at baseline and on days 3, 7, 14, 28, and 35. With the ISGA, patients are rated as clear, almost clear, mild, moderate, severe, or very severe. Treatment success was defined as a rating of clear or almost clear. All other ratings were treatment failures.
At the end of 4 weeks, 51% of the AN0128 group reached a level of clear or almost clear, vs. 37% of controls.
PARIS — An investigational anti-inflammatory drug shows promise in reducing the severity of mild to moderate atopic dermatitis, Dr. Karl Beutner said in a poster presentation at the annual meeting of the European Society for Dermatological Research.
A total of 103 patients with mild to moderate atopic dermatitis (body surface area 3%–10%) were randomized to twice-daily treatment with 1% AN0128 (67 patients)—AN0128 has been shown to block inflammatory cytokines in vitro—or the vehicle cream (36 patients) for 4 weeks, wroteDr. Beutner, chief medical officer of Anacor Pharmaceuticals Inc. in Palo Alto, Calif.
Subjects were evaluated with the six-point Investigator's Static Global Assessment at baseline and on days 3, 7, 14, 28, and 35. With the ISGA, patients are rated as clear, almost clear, mild, moderate, severe, or very severe. Treatment success was defined as a rating of clear or almost clear. All other ratings were treatment failures.
At the end of 4 weeks, 51% of the AN0128 group reached a level of clear or almost clear, vs. 37% of controls.